The study is looking at a new treatment called COYA 302 for people with Amyotrophic Lateral Sclerosis (ALS), a disease that affects the nerves and muscles. This treatment is being tested to see if it is safe and works well. COYA 302 includes two components: a small amount of a protein called interleukin-2 (IL-2) and a drug similar to abatacept, which helps control the immune system. Participants will be randomly given either COYA 302 or a placebo (a harmless substance) for 24 weeks, and those who finish might receive COYA 302 for another 24 weeks.
The study will measure changes in disease progression using tools like the ALS Functional Rating Scale-Revised (ALSFRS-R) and will also monitor for safety and side effects.
- Study Length: Up to 48 weeks.
- Locations: Conducted across 20-25 sites in the US and Canada.
- Eligibility: Adults aged 18-80 with a recent ALS diagnosis.
How understandable was the trial content above?
Hard to understand
Easy to understand